Deciphera Pharmaceuticals LLC., a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer, has entered into a definitive merger agreement with Ono Pharmaceutical Company, Ltd. (ONO) under which ONO will acquire all outstanding shares of Deciphera common stock in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO, for a total equity value of $2.4 billion.
 
The boards of directors of both companies have unanimously approved the transaction.

Delivering New Oncology Drugs and Serving Patients

Together, ONO and Deciphera aim to accelerate their shared vision to deliver innovative new drugs and serve patients around the world.
 
Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK, Deciphera’s switch-control inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST), which is approved in the United States and over 40 other countries, Deciphera also brings a mature, diverse pipeline of potential medicines, including vimseltinib, DCC-3116 (an ULK inhibitor) and multiple additional oncology candidates.
 
The Acquisition is expected to enable ONO to build a robust presence in oncology, one of its key priority areas, and also support ONO’s efforts to become a Global Specialty Pharma company.
 
Steven L. Hoerter, President and CEO of Deciphera, said, “Deciphera and ONO share a deep commitment to improving the lives of people living with cancer, and the transaction announced today enables us to make an even greater impact for patients. Together, we expect to advance and accelerate each organization’s important work through combined research and development capabilities and a global commercial footprint. Importantly, this acquisition delivers for all of Deciphera’s stakeholders. It provides immediate, compelling value for our shareholders, provides greater opportunities for our world-class team, and ultimately, greater hope for patients.”
 
“We expect that this acquisition of Deciphera will not only expand ONO’s target oncology portfolio, but also accelerate ONO’s business development in the United States and Europe, and strengthen kinase drug discovery research,” said Gyo Sagara, Representative Director, Chairman of the Board and CEO of ONO. “We respect the innovative culture of Deciphera and look forward to working together to drive further growth for both ONO and Deciphera.”

Related News

Read Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.